Kagan KO, Enders M, Hoopmann M, et al. - Via this ongoing observational study, researchers sought to report on the efficacy of hyperimmunoglobulin (HIG) treatment in women with a recent primary cytomegalovirus (CMV) infection up to 14 weeks' gestation. Following were included in the enrolment criteria: presence of confirmed recent primary CMV infection in the first trimester and a gestational age at first HIG administration of ≤ 14 weeks. Administration of HIG at a dose of 200 IU/kg maternal body weight was begun intravenously as soon as possible within a few days after the first visit. Repetition of the dose was done every 2 weeks until about 18 weeks' gestation. A total of 149 pregnancies (153 fetuses) completed the treatment. Per outcomes, maternal–fetal CMV transmission can be prevented by providing hyperimmunoglobulin (HIG) treatment if patients are well selected. They emphasize discussing administration of HIG in cases of a primary CMV infection in the first trimester. Success with HIG treatment was mostly obtained in women with a recent primary infection in the first trimester or during the periconceptional period, and when HIG administration was done at a biweekly dose of 200 IU/kg.